A 14-protein blood test predicts lung cancer risk more than 5 years before detection, including in never-smokers outside current screening criteria.
- In the news
Moving in Cancer Discovery.
Rebuilt
A 14-protein blood test predicts lung cancer risk more than 5 years before detection, including in never-smokers outside current screening criteria.
Newest first · last 60 days
High γδ T cell infiltration in small cell lung cancer predicts improved response to anti-PD-L1 immunotherapy.
γδ T cells activated by a BiTE can target small cell lung cancer independently of MHC-I expression, overcoming limitations of CD8+ T cell responses.
Optimal radioimmunotherapy strategies require balancing local tumor control with systemic immune activation, with some combinations improving survival in specific cancer types.
A rare inherited EGFR mutation has persisted in Southern Appalachia since the 1700s, now affecting populations and increasing lung cancer risk.
Small cell lung cancer exhibits a high 80% rate of brain metastases driven by neurotropic mechanisms and resistance to current therapies.
Tambotatug pelitecan significantly improves survival and response rates in relapsed small-cell lung cancer compared to topotecan, with fewer severe adverse events.
Heterogeneous resistance mechanisms, including EGFR mutations, bypass signaling, and transformation, emerge in EGFR T790M-positive lung adenocarcinoma after 14.2 months of osimertinib treatment.
Proteomic analysis of 267 neuroendocrine carcinomas reveals five subtypes with distinct molecular and therapeutic vulnerabilities, including NAD+ dependency in subtype H.
Journals this month
Topics moving, week to 23 Oct 2026